The 12th edition of BioAsia 2015 which is scheduled to be held February 2- 4, 2015 in Hyderabad is going to focus on seven critical areas relating to life sciences and healthcare to identify new opportunities and avenues in the biotechnology and pharmaceutical sector. The focus areas that are expected to be deliberated during the upcoming BioAsia 2015 include ‘drug discovery and India’s innovation pipeline’, ‘digital health and healthcare IT’, ‘clinical research’, ‘supply chain and logistics', ‘rapid diagnostics’, ‘medical electronics and devices’, and ‘public health & access.

This time the big event is moulded in accordance with India’s reform programme in various sectors. The annual international life sciences conference is expected to unveil the theme ‘New Opportunities in the Transition’ in the field of life sciences & health care industry.

Unlike earlier editions, this time BioAsia 2015 has moulded its theme to the tune of government initiative to attract more investors. Moreover, since its inception the various editions of BioAsia have been acting as a catalyst towards bringing attention to the industry in India and its potential, adding momentum to the ‘Make In India’ focus of the government of India.

Currently, the Indian biotechnology sector is one of the fastest growing knowledge based sectors in India and holds high promise in shaping India’s rapidly developing economy, given the global transformation and need for more affordable medicines. With cost containment measures and moves to cut health expenditures by Governments across continents, the pressure on global drug industry to reap more from less is palpable. Catching up with this changing model, the industry has been embracing joint ventures and partnerships and easing itself out of non-core and growing into specialised segments. As an emerging model in the hunt for molecules and cutting down on cost of development, local innovations is gaining importance. The market focus for Big Pharma has simultaneously shifted to developing economies, most distinctly visible in Asian countries like India and China.

This time BioAsia 2015 will have various highlights relating to biotech industry and is expected to symbolise the transitioning phase of Indian life sciences industry. As many as  60 high profile speakers from across 50 countries across the globe are expected to participate. The international conference is expected to conduct 40 plus seminars and presentation sessions where in more than 700 corporates from across the globe will participate in the big event.

Describing the event as most relevant for the contemporary industry, “The important topics relevant to the Indian contest such as drug discovery and India’s innovation pipeline, clinical research, supply chain and logistics, rapid diagnostics and public health & access will be deliberated and a special conference on the topic of ‘Digital health and healthcare IT will be deliberated during BioAsia 2015. The event is designed to offer the right opportunities to catch the right notes and develop strategies to succeed in emerging markets like India,” said Shakthi Nagappan, CEO BioAsia.